Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.62 |
| ▸ | LMNA | P02545 | 3/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.62 |
| ▸ | HPGD | P15428 | 2/20 | 0.62 |
| ▸ | POLB | P06746 | 2/20 | 0.62 |
| ▸ | BLM | P54132 | 1/20 | 0.62 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.62 |
| ▸ | OGA | O60502 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 5/20 | 0.55 |
| ▸ | RAB9A | P51151 | 5/20 | 0.55 |
| ▸ | MAPT | P10636 | 5/20 | 0.55 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10464669 | 0.99 | ALDH1A1 (0.64) | ALDH1A1KMT2ALMNAMEN1L3MBTL1 | |
| SCHEMBL10466693 | 0.89 | OGA (0.56) | ALDH1A1KMT2ALMNAMEN1L3MBTL1 | |
| SCHEMBL10464496 | 0.89 | OGA (0.53) | ALDH1A1KMT2ALMNAMEN1L3MBTL1 | |
| SCHEMBL5378395 | 0.88 | OGA (0.53) | ALDH1A1KMT2ALMNAMEN1L3MBTL1 | |
| SCHEMBL7173774 | 0.88 | OGA (0.55) | ALDH1A1KMT2ALMNAMEN1L3MBTL1 | |
| SCHEMBL5723882 | 0.87 | OGA (0.52) | ALDH1A1KMT2ALMNAMEN1L3MBTL1 | |
| SCHEMBL1118526 | 0.87 | OGA (0.54) | ALDH1A1KMT2ALMNAMEN1L3MBTL1 | |
| Hydrochloric Acid SCHEMBL2584196 | 0.87 | MAPT (0.53) | ALDH1A1KMT2ALMNAMEN1L3MBTL1 | |
| SCHEMBL3436232 | 0.86 | RAB9A (0.55) | ALDH1A1KMT2ALMNAMEN1L3MBTL1 | |
| SCHEMBL15888544 | 0.85 | OGA (0.53) | ALDH1A1KMT2ALMNAMEN1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11834452-B2 | CXCR7 antagonists | CHEMOCENTRYX, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-11834452-B2 | CXCR7 antagonists | CHEMOCENTRYX, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-11834452-B2 | CXCR7 antagonists | CHEMOCENTRYX, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-20220127272-A1 | CXCR7 ANTAGONISTS | CHEMOCENTRYX, INC. | 2022-04-28 | — | — | US | disclosed |
| US-20220127272-A1 | CXCR7 ANTAGONISTS | CHEMOCENTRYX, INC. | 2022-04-28 | — | — | US | disclosed |
| US-11059825-B2 | CXCR7 antagonists | CHEMOCENTRYX, INC. (US) | 2021-07-13 | — | — | US | disclosed |
| US-11059825-B2 | CXCR7 antagonists | CHEMOCENTRYX, INC. (US) | 2021-07-13 | — | — | US | disclosed |
| US-20200095251-A1 | CXCR7 ANTAGONISTS | CHEMOCENTRYX, INC. | 2020-03-26 | — | — | US | disclosed |
| US-10287292-B2 | CXCR7 antagonists | CHEMOCENTRYX, INC. (US) | 2019-05-14 | — | — | US | disclosed |
| US-10287292-B2 | CXCR7 antagonists | CHEMOCENTRYX, INC. (US) | 2019-05-14 | — | — | US | disclosed |
| WO-1994014436-A1 | RETROVIRAL PROTEASE INHIBITING COMPOUNDS | ABBOTT LABORATORIES (US) | 1994-07-07 | — | — | WO | disclosed |
| US-4904792-A | N-thiazolymethylthioalkyl-N'-alkylamidines and related compounds | ELI LILLY AND COMPANY (US) | 1990-02-27 | — | — | US | disclosed |
| US-4760075-A | Miticides | ELI LILLY AND COMPANY (US) | 1988-07-26 | — | — | US | disclosed |
| EP-0091220-B1 | THIAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ELI LILLY AND COMPANY (US) | 1987-05-13 | — | — | EP | disclosed |
| EP-0049618-B1 | IMPROVEMENTS IN OR RELATING TO 2,4-DISUBSTITUTED THIAZOLE DERIVATIVES | ELI LILLY AND COMPANY (US) | 1985-08-14 | — | — | EP | disclosed |
| US-4474794-A | N-Thiazolylmethylthioalkyl-N1 -alkenyl (or alkynyl)guanidines and related compounds | ELI LILLY AND COMPANY (US) | 1984-10-02 | — | — | US | disclosed |
| EP-0091220-A2 | Thiazole derivatives, process for their preparation and pharmaceutical compositions containing them | ELI LILLY AND COMPANY (US) | 1983-10-12 | — | — | EP | disclosed |
| US-4382090-A | N-Thiazolylmethylthioalkyl-N'alkylamidines and related compounds | ELI LILLY AND COMPANY (US) | 1983-05-03 | — | — | US | disclosed |
| US-4375547-A | ANTIHISTAMINES, 'I RECEPTOR ANTAGONISTS, ANTISECRETORY AGENTS | ELI LILLY AND COMPANY (US) | 1983-03-01 | — | — | US | disclosed |
| EP-0049618-A1 | Improvements in or relating to 2,4-disubstituted thiazole derivatives | ELI LILLY AND COMPANY (US) | 1982-04-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10287292-B2 | CXCR7 antagonists | CXCR1, CXCR5, CCR7 | ALDH1A1 1699/4885KMT2A 4596/4885LMNA 4819/4885 |
| US-11059825-B2 | CXCR7 antagonists | CXCR1, CXCR5, CCR7 | ALDH1A1 1699/4885KMT2A 4596/4885LMNA 4819/4885 |
| US-11834452-B2 | CXCR7 antagonists | CXCR1, CXCR5, CCR7 | ALDH1A1 1699/4885KMT2A 4596/4885LMNA 4819/4885 |
| US-20200095251-A1 | CXCR7 ANTAGONISTS | CXCR1, CXCR5, CCR7 | ALDH1A1 1699/4885KMT2A 4596/4885LMNA 4819/4885 |
| US-20220127272-A1 | CXCR7 ANTAGONISTS | CXCR1, CXCR5, CCR7 | ALDH1A1 1699/4885KMT2A 4596/4885LMNA 4819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.